Innoviva Market Cap 2010-2024 | INVA

Innoviva market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of November 04, 2024 is $1.21B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.211B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $765.281B 79.27
Novo Nordisk (NVO) Denmark $492.372B 37.58
Johnson & Johnson (JNJ) United States $380.982B 15.45
AbbVie (ABBV) United States $354.099B 18.65
Merck (MRK) United States $258.017B 17.12
Novartis AG (NVS) Switzerland $225.903B 15.02
AstraZeneca (AZN) United Kingdom $221.475B 19.73
Pfizer (PFE) United States $157.307B 10.76
Sanofi (SNY) $134.378B 12.17